Abstract 140P
Background
The high recurrence rate after surgical resection remains a big challenge for long-term survival of HCC patients. In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of perioperative treatment. This study aimed to evaluate the efficacy and safety of combining tislelizumab with Lenvatinib and TACE as neoadjuvant therapy in resectable CNLC IIa-IIb HCC patients.
Methods
This study (ClinicalTrials.gov NCT06003673) enrolled patients with primary resectable HCC of CNLC IIa-IIb who had not received prior systemic therapy. For CNLC IIa patients must meet one of the following criteria: unclear tumor boundaries, proximity to blood vessels, or suspicious residual margins. TACE will be performed once only on Day 1. Tislelizumab (200 mg, IV, Q3W) and lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily was initiated on Day1. All patients undergo 2 cycles of neoadjuvant therapy. Patients will undergo surgical resection within 2-4 weeks after neoadjuvant treatment depends on the investigators’ evaluation. Primary endpoint was relapse-free survival (RFS). Secondary endpoints were objective response rate (ORR) by RECIST v1.1, Pathological Complete Response Rate (pCR), Major pathological reactions (MPR), R0 resection rates, overall survival (OS), and adverse events (AE).
Results
Between July 2023 and August 2024, 23 patients were enrolled. As of September 29, 2024, after a median follow-up of 9.4 months. All patients received neoadjuvant, and 19 patients underwent successful R0 resection, 7 patients (7/19,36.9%) achieved complete pathological response, 10 patients (10/19, 52.6%) achieved major pathological reaction (necrosis > 90%). The median age was 59 years old,all Child-Pugh A(100%), ECOG PS 0(100%), mostly males (82.6%), HBV infection (76.2%), BCLC B(100%) and CNLC IIa (63.6%). No grade 4 or 5 TRAE were observed. Median RFS and overall survival were not reached.
Conclusions
Lenvatinib, tislelizumab, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC of CNLC IIa-IIb . Further follow up will continue.
Clinical trial identification
NCT06003673.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract